(Q34068916)

30 July 2017

title

Non-vision adverse events with vigabatrin therapy (English)

1 reference

30 July 2017

1 reference

ChEBI release 2020-05-28

S D Walker

1

1 reference

30 July 2017

R Kälviäinen

series ordinal

2

1 reference

30 July 2017

publication date

1 January 2011

1 reference

Acta neurologica Scandinavica. Supplementum

30 July 2017

published in

1 reference

30 July 2017

issue

192

1 reference

30 July 2017

page(s)

72-82

1 reference

Effect of elevated brain GABA concentrations on the actions of bicuculline and picrotoxin in mice

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Mechanism of action of vigabatrin: correcting misperceptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Effects of vigabatrin on partial seizures and cognitive function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Dose-Response Study of Vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Randomized trial of vigabatrin in patients with infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Vigabatrin for the treatment of infantile spasms: final report of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Vigabatrin therapy for refractory complex partial seizures: review of major European trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Vigabatrin therapy for refractory complex partial seizures: review of clinical trial experience in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

21 January 2018

Vigabatrin: 2008 update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Understanding and interpreting vision safety issues with vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Hormonal aspects of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Sexual and reproductive dysfunction associated with antiepileptic drug use in men with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

21 January 2018

Epilepsy and menopause.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Antiepileptics and bone health

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

The potential for vigabatrin-induced intramyelinic edema in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Effects of vigabatrin on evoked potentials in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Development of vigabatrin-induced lesions in the rat brain studied by magnetic resonance imaging, histology, and immunocytochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Vigabatrin: no microvacuoles in a human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Absence of cortical white matter changes in three patients undergoing long-term vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Vigabatrin (gamma-vinyl-GABA): neuropathologic evaluation in five patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Cerebral MRI abnormalities associated with vigabatrin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Vigabatrin-associated diffusion MRI abnormalities in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Anticonvulsant-induced psychiatric disorders. The role of forced normalisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Suicidal behavior and antiepileptic drugs in epilepsy: analysis of the emerging evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

21 January 2018

Vigabatrin and psychosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Psychiatric adverse events during vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

Acute psychological disorders in patients with epilepsy: a nation-wide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01602.X

10.1111/J.1600-0404.2011.01602.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference